Hepatic encephalopathy (West Haven criteria) is a complex, potentially reversible spectrum of neuropsychiatric abnormalities occurring in patients with acute liver failure, chronic liver disease, or significant portosystemic shunting 1, 4. As one of the most severe and burdensome complications of decompensated cirrhosis, it is characterized by disturbances ranging from subtle cognitive and psychomotor deficits to profound deep coma 3, 5. Because the diseased liver and portosystemic collateral vessels fail to clear gut-derived neurotoxins—principally ammonia—these substances accumulate in systemic circulation, cross the blood-brain barrier, and cause astrocytic dysfunction, neurotransmitter imbalance, and low-grade cerebral edema 4. Recognizing clinical manifestations across this wide severity spectrum is critical for prompt identification, elimination of precipitating factors, and initiation of targeted medical therapy to reduce morbidity and mortality 3, 5.
Etiology & Risk Factors
- Chronic Liver Disease & Cirrhosis: Advanced parenchymal destruction resulting in decreased functional hepatocellular mass and extensive portosystemic collateral shunting, allowing nitrogenous gut toxins to bypass hepatic first-pass metabolism 1, 4.
- Acute Liver Failure (ALF): Rapid massive necrosis of hepatocytes (e.g., from acetaminophen toxicity, viral hepatitis, or drug-induced liver injury) leading to fulminant cerebral edema and intracranial hypertension without pre-existing portal-systemic collaterals 3, 6.
- Precipitating Triggers in Overt Hepatic Encephalopathy:
- Gastrointestinal Bleeding: Breakdown of blood in the gastrointestinal tract floods the lumen with an enormous nitrogenous and protein load, converting into massive ammonia production by colonic bacteria 1.
- Infections: Spontaneous bacterial peritonitis (SBP), urinary tract infections, and pneumonia induce systemic inflammation, cytokine release, and synergistically worsen encephalopathy 4.
- Electrolyte & Metabolic Disturbances: Hypokalemia, metabolic alkalosis (which enhances non-ionic ammonia diffusion across the blood-brain barrier), hyponatremia, and uremia 1.
- Constipation: Prolonged colonic transit time increases bacterial metabolism and mucosal absorption of nitrogenous waste products 1, 4.
- Iatrogenic Insults: Administration of sedatives, tranquilizers, opioids, or excessive loop diuretics leading to volume contraction, renal impairment, and electrolyte shifts 1.
- Dietary Protein Excess: Rare primary dietary triggers, though severe protein restriction is no longer recommended 2.
- Surgical & Interventional Risks: Placement of transjugular intrahepatic portosystemic shunts (TIPS) or spontaneous large portosystemic shunts that acutely divert portal blood away from the hepatic parenchyma 2, 7.
Pathophysiology
The pathogenesis of hepatic encephalopathy is multifactorial, driven primarily by hyperammonemia, systemic inflammation, and synergistic oxidative and nitrosative stress 4. Under normal physiological conditions, ammonia generated by bacterial breakdown of dietary protein in the gut is absorbed via the portal vein and converted into urea in the liver via the urea cycle. In cirrhosis or acute liver failure, hepatocellular dysfunction and portosystemic shunting allow neurotoxins to enter the systemic circulation.
Once systemic ammonia crosses the blood-brain barrier, astrocytes—the primary site of cerebral ammonia detoxification—use the enzyme glutamine synthetase to combine ammonia with glutamate, forming glutamine. The intracellular accumulation of osmotically active glutamine triggers compensatory extrusion of organic osmolytes, resulting in astrocyte swelling, mitochondrial dysfunction, and low-grade cerebral edema 4. Furthermore, elevated glutamine levels alter amino acid transport across the blood-brain barrier, disrupting central neurotransmission. This manifests as an upregulation of inhibitory tone (mediated by gamma-aminobutyric acid [GABA] and neurosteroids acting on GABA-A receptors) and a simultaneous impairment of excitatory glutamatergic neurotransmission, ultimately dampening cortical oscillatory networks and causing global neurological depression 3, 4.
Clinical Presentation & Classic Clinical Signs
- History & Cardinal Symptoms:
- Covert / Minimal Encephalopathy: Subtle neurocognitive deficits, daytime somnolence, altered sleep-wake cycles (insomnia alternating with hypersomnia), mild deficits in attention, working memory, and impaired psychomotor speed or fine motor dexterity (impacting driving safety) 3, 5.
- Overt Encephalopathy: Progressive disorientation to time and place, personality changes, inappropriate behavior, lethargy, confusion, slurred speech, stupor, and ultimately unresponsiveness leading to deep coma 3, 5.
- Physical Examination & Named Clinical Signs:
- Asterixis (Flapping Tremor): A classic neurological sign elicited by asking the patient to extend both arms with wrists dorsiflexed and fingers spread. Sudden lapses in wrist and finger extension cause a brief, irregular flapping motion, reflecting a temporary loss of postural muscle tone due to diencephalic motor inhibition 1, 3.
- Fetor Hepaticus: A musty, sweet, slightly fecal or garlic-like breath odor caused by mercaptans and dimethyl sulfide escaping into the lungs via portosystemic collaterals without hepatic clearance 1.
- Neurological Signs: Hyperreflexia in early stages, progressing to hyporeflexia, extensor plantar responses (Babinski sign) in advanced coma, muscle rigidity, and clonus. Decerebrate or decuricating posturing may be observed in fulminant cases with cerebral edema 1, 6.
- Stigmata of Chronic Liver Disease: Spider angiomata, palmar erythema, jaundice, ascites, splenomegaly, caput medusae, and muscle wasting 1, 7.
Diagnostic Workup & Interpretation (Laboratory, Imaging & ECG/Pathology)
| Diagnostic Modality / Test | Expected Clinical & Radiological / Laboratory Finding |
|---|---|
| Gold-Standard Investigation | Psychometric Hepatic Encephalopathy Score (PHES) battery, Critical Flicker Frequency (CFF), or Animal Naming Test for minimal/covert HE; clinical grading via West Haven criteria for overt HE 2, 4. |
| Laboratory Panel | Elevated venous or arterial blood ammonia levels (though non-diagnostic in isolation; useful to exclude HE when normal or assess prognosis in ALF); coagulopathy (elevated PT/INR), thrombocytopenia, hyperbilirubinemia, elevated transaminases (in acute) or normal-to-low transaminases with hypoalbuminemia (in chronic cirrhosis) 1, 6. |
| Imaging / Radiology (X-ray, US, CT, MRI) | Brain MRI may demonstrate symmetrical hyperintensity in the globus pallidus on T1-weighted sequences due to manganese and type II Alzheimer astrogliosis; head CT rules out intracranial hemorrhage, subdural hematoma, or acute structural stroke; abdominal ultrasound/Doppler assesses liver parenchymal echogenicity, portal vein patency, and portosystemic collaterals 1, 4. |
| ECG / Histopathology / Procedural | Electroencephalography (EEG) reveals progressive generalized slowing (triphasic waves at 2–3 Hz, shifting from alpha to theta and delta waves) in overt HE; diagnostic paracentesis to rule out spontaneous bacterial peritonitis as a precipitating trigger 1, 4, 6. |
Staging, Classification & Clinical Scoring Systems
| Criterion / Stage / Score Component | Clinical Threshold, Points & Management Implication |
|---|---|
| West Haven Grade 0 (Minimal / Covert) | Normal clinical mental status; subtle deficits detected only on psychometric or neurophysiological testing (e.g., PHES, block design, number connection tests). No overt daily impairment 1, 2. |
| West Haven Grade 1 (Overt - Mild) | Trivial lack of awareness, euphoria or anxiety, shortened attention span, impaired performance on addition or subtraction. Sleep pattern inversion often noted 1, 3. |
| West Haven Grade 2 (Overt - Moderate) | Lethargy or apathy, disorientation to time (disoriented to month or year), subtle personality change, inappropriate behavior, obvious asterixis present 1, 3. |
| West Haven Grade 3 (Overt - Severe) | Somnolence to semi-stupor, responsive to verbal stimuli, confused, gross disorientation to place and time, incoherent speech, bizarre behavior 1, 3. |
| West Haven Grade 4 (Coma) | Unresponsive to verbal or noxious stimuli, absence of purposeful movement, flaccid or rigid posturing. High mortality risk; mandates intensive care unit admission and airway protection 1, 3. |
| Child-Pugh & MELD-Na Scores | Quantify underlying liver disease severity and prioritize patients for orthotopic liver transplantation consideration when encephalopathy becomes refractory 1, 2. |
Differential Diagnosis
| Differential Condition | Distinguishing Clinical, Biochemical & Imaging Features |
|---|---|
| Wernicke Encephalopathy | Ophthalmoplegia, ataxia, and confusion caused by thiamine deficiency; lacks asterixis and has normal or low ammonia levels; responds promptly to parenteral thiamine 1. |
| Intracranial Bleeding / Stroke | Focal neurological deficits, asymmetric motor or sensory findings, acute onset on head CT or MRI, inconsistent with generalized metabolic encephalopathy 1. |
| Uremic Encephalopathy | Markedly elevated blood urea nitrogen (BUN) and creatinine, asterixis present, but lacks severe hepatocellular synthetic dysfunction unless concurrent hepatorenal syndrome is present 1. |
| Alcohol Withdrawal / Delirium Tremens | Autonomic hyperactivity (tachycardia, hypertension, diaphoresis), visual or tactile hallucinations, tremors rather than pure flapping asterixis, history of recent alcohol cessation 1. |
Management & Treatment Protocol
- Initial Stabilization & Resuscitation:
- Assess airway, breathing, and circulation (ABCDEs). Patients with West Haven Grade 3 or 4 encephalopathy are at high risk of aspiration and require early endotracheal intubation and intensive care unit (ICU) admission 1, 3.
- Rigorous identification and treatment of all precipitating triggers (e.g., empiric antibiotics for suspected infection, urgent upper endoscopy for acute variceal bleeding, correction of electrolyte abnormalities) 2, 4.
- First-Line Medical / Pharmacological Therapy (with exact adult dosing):
- Lactulose (Non-absorbable disaccharide): Administer 25–30 mL (15–20 g) orally every 1–2 hours until the patient evacuates 2–3 soft stools daily. For unconscious patients, lactulose 300 mL mixed in 700 mL of water can be administered via retention enema every 4–6 hours. Lactulose is metabolized by colonic bacteria into short-chain fatty acids, lowering stool pH, trapping ammonia in the lumen as ammonium ($\text{NH}_4^+$), and accelerating colonic transit 2, 4.
- Rifaximin (Non-absorbable antibiotic): Administer 550 mg orally twice daily as an add-on therapy to lactulose for the prevention of recurrent overt hepatic encephalopathy. Rifaximin targets ammonia-producing colonic bacteria and reduces systemic neurotoxin burden 2, 4.
- Second-Line & Alternative Agents:
- L-ornithine L-aspartate (LOLA) intravenously or orally to stimulate the urea cycle and glutamine synthesis in skeletal muscle 4, 5.
- Alternative cathartics (polyethylene glycol) or branched-chain amino acid (BCAA) supplementation in patients intolerant to standard protein diets 2.
- Surgical & Interventional Indications:
- Embolization of large spontaneous portosystemic shunts (SPSS) via transhepatic or retrograde transvenous techniques in patients with recurrent refractory hepatic encephalopathy despite optimal medical therapy 2, 7.
- Evaluation for orthotopic liver transplantation (OLT) in patients with decompensated cirrhosis and refractory hepatic encephalopathy, as it represents the definitive curative option 1, 2.
Complications & Prognosis
- Acute Complications: Aspiration pneumonia, severe anoxic brain injury, cerebral herniation (predominantly in acute liver failure), acute kidney injury (hepatorenal syndrome), and profound metabolic instability 1, 3, 6.
- Long-Term Morbidity & Mortality: The development of overt hepatic encephalopathy signals advanced hepatic decompensation and portends a poor 1-year survival rate without liver transplantation, with cumulative survival dropping significantly after the first overt episode 2, 5.
- Prognostic Indicators: Higher Child-Pugh class, elevated MELD score, recurrent unprovoked episodes, failure to respond to dual lactulose and rifaximin therapy, and the presence of precipitating sepsis are associated with markedly increased short-term mortality 1, 2.